Kidney / Renal
- (101-21) A Phase 1 Multicenter, Open-label, Dose-Escalation, Safety, Pharmacodynamic,
Pharmacokinetic Study of Q702 with a Cohort Expansion at the RP2D in Patients
with Advanced Solid Tumors
- (114-19) A Phase 1, open label, first-in-human study of TR1801-ADC, an
antibody drug conjugate (ADC), in patients with select solid tumors expressing c-Met
- (155-17) 0C 17-1: Phase 1 Multi-center Study of the Safety Pharmacokinetics
and Preliminary Efficacy of CBT-101 in Subjects with Advanced Solid Tumors
and C-Met Dysregulation
-
(178-18) A Phase 1-2 Study of the Safety, Pharmacokinetics, and Activity
of ASTX029 in Subjects With Advanced Solid Tumors
-
(187-19) A Phase 1/2 Study of AGEN1181, an Fc-Engineered Anti-CTLA-4 Monoclonal
Antibody as Monotherapy and in Combination With AGEN2034, an Anti-PD-1
Monoclonal Antibody, in Subjects with Advanced Cancer
-
(189-18) ⁸⁹Zr-Df-IAB22M2C (CD8 PET Tracer) for PET/CT in Patients With
Metastatic Solid Tumors
- (205-19) Study to Assess AFM24 in Advanced Solid Cancers
-
(214-17) A Phase 1/2 First-in-human Study of BMS-986258 Alone and in Combination
with Nivolumab in Advanced Malignant Tumors
Certain clinical trials may not be listed on ClinicalTrials.gov. To learn
more about these or other clinical trials, please call 949-764-5543 or
contact us online.